Vietnamese (HOSE) Pharma Industry Analysis

Industry Valuation and Performance

Has the Vietnamese Pharma Industry valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Sun, 10 May 2026	₫46.5t	₫23.1t	₫2.3t	15.3x	19.9x	2x
Tue, 07 Apr 2026	₫48.3t	₫23.1t	₫2.3t	16x	20.6x	2.1x
Thu, 05 Mar 2026	₫48.9t	₫22.8t	₫2.4t	16.3x	20.1x	2.1x
Sat, 31 Jan 2026	₫49.1t	₫22.6t	₫2.4t	16.5x	20.3x	2.2x
Mon, 29 Dec 2025	₫47.1t	₫21.6t	₫2.3t	16.2x	20.3x	2.2x
Wed, 26 Nov 2025	₫46.4t	₫21.6t	₫2.3t	16.4x	20x	2.1x
Fri, 24 Oct 2025	₫47.2t	₫21.3t	₫2.3t	18x	20.1x	2.2x
Sun, 21 Sep 2025	₫46.8t	₫21.1t	₫2.3t	16.8x	20.8x	2.2x
Tue, 19 Aug 2025	₫46.7t	₫21.1t	₫2.3t	17.1x	20.7x	2.2x
Thu, 17 Jul 2025	₫45.9t	₫20.6t	₫2.2t	18.6x	20.8x	2.2x
Sat, 14 Jun 2025	₫45.5t	₫20.6t	₫2.2t	18.1x	20.7x	2.2x
Mon, 12 May 2025	₫46.2t	₫20.7t	₫2.2t	18.2x	21x	2.2x
Wed, 09 Apr 2025	₫40.9t	₫20.4t	₫2.2t	15.6x	18.7x	2x
Fri, 07 Mar 2025	₫46.8t	₫20.5t	₫2.2t	17x	21.5x	2.3x
Sun, 02 Feb 2025	₫47.0t	₫19.5t	₫2.2t	17.6x	21.9x	2.4x
Tue, 31 Dec 2024	₫47.7t	₫19.3t	₫2.1t	17.2x	23.2x	2.5x
Thu, 28 Nov 2024	₫44.4t	₫19.3t	₫2.1t	16.8x	21.6x	2.3x
Sat, 26 Oct 2024	₫44.5t	₫19.3t	₫2.1t	15.7x	21.5x	2.3x
Mon, 23 Sep 2024	₫45.6t	₫19.4t	₫2.1t	15.7x	21.6x	2.4x
Wed, 21 Aug 2024	₫43.9t	₫19.4t	₫2.1t	15.8x	20.8x	2.3x
Fri, 19 Jul 2024	₫46.1t	₫19.2t	₫2.2t	15.4x	20.9x	2.4x
Sun, 16 Jun 2024	₫42.3t	₫19.2t	₫2.2t	15.5x	19.2x	2.2x
Tue, 14 May 2024	₫40.3t	₫19.2t	₫2.2t	14.9x	18.3x	2.1x
Thu, 11 Apr 2024	₫39.9t	₫19.0t	₫2.4t	14.5x	16.8x	2.1x
Sat, 09 Mar 2024	₫38.9t	₫19.0t	₫2.4t	14.2x	16.1x	2x
Mon, 05 Feb 2024	₫37.6t	₫19.0t	₫2.4t	13.6x	15.7x	2x
Wed, 03 Jan 2024	₫37.5t	₫18.4t	₫2.4t	14.5x	15.5x	2x
Fri, 01 Dec 2023	₫36.4t	₫18.4t	₫2.4t	13.8x	15.1x	2x
Sun, 29 Oct 2023	₫36.5t	₫16.7t	₫2.4t	13.2x	15.5x	2.2x
Tue, 26 Sep 2023	₫38.8t	₫16.9t	₫2.4t	13.2x	16x	2.3x
Thu, 24 Aug 2023	₫38.4t	₫16.9t	₫2.4t	12.9x	15.8x	2.3x
Sat, 22 Jul 2023	₫41.5t	₫16.7t	₫2.4t	14.4x	17.4x	2.5x
Mon, 19 Jun 2023	₫38.6t	₫16.7t	₫2.3t	14x	16.5x	2.3x
Wed, 17 May 2023	₫34.8t	₫16.7t	₫2.3t	13.2x	14.9x	2.1x

Current Industry PE

Investors are relatively neutral on the Vietnamese Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.

The industry is trading close to its 3-year average PE ratio of 19.2x.

The industry is trading close to its 3-year average PS ratio of 2.2x.

Past Earnings Growth

The earnings for companies in the Pharmaceuticals industry have remained mostly flat over the last three years.
Meanwhile revenues for these companies have grown 12% per year.
This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased and as a result, profits have held steady.

Industry Trends

Which industries have driven the changes within the Vietnamese Healthcare industry?


VN Market	3.03%
Healthcare	-0.30%
Pharma	-0.18%
Pharma	-0.18%

Industry PEThere are no additional sub-industries under this industry.

Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

Company	Last Price	7D	1Y	Valuation
DHG DHG Pharmaceutical	₫101.90k	1.9% +₫248.4b	-3.7%	PE15.3x
TRA Traphaco	₫80.00k	3.9% +₫124.4b	7.1%	PE15.3x
DCL Cuu Long Pharmaceutical	₫38.10k	2.1% +₫58.4b	48.8%	PS2.1x
OPC OPC Pharmaceutical	₫23.50k	3.5% +₫51.2b	-0.8%	PE15.8x
DP3 Central Pharmaceutical No3	₫59.50k	1.7% +₫21.5b	10.4%	PE7.8x

Livzon Pharmaceutical Group Inc. (SZSE:000513) acquired 67.88% stake in Imexpharm Corporation (HOSE:IMP) from SK Investment Vina III Pte Ltd., Cong Ty Co Phan Dau Tu Binh Minh Kim and KBA Investment joint stock company for VND 6 trillion.

Livzon Pharmaceutical Group Inc. (SZSE:000513) signed Framework Agreement to acquire 77.94% stake in Imexpharm Corporation (HOSE:IMP) from SK Investment Vina III Pte Ltd., Cong Ty Co Phan Dau Tu Binh Minh Kim and KBA Investment joint stock company for VND 6.9 trillion on May 22, 2025. A cash consideration of VND 5.73 trillion will be paid by Livzon Pharmaceutical Group Inc. As part of consideration, VND 5.73 trillion is paid towards common equity of Imexpharm Corporation. The Acquisition will be funded by the Group’s internal resources. The Acquisition will lay a solid foundation for the Group’s further expansion into overseas markets, supporting its long-term strategy of internationalization and sustainable development in the pharmaceutical sector. On December 29, 2025, the parties signed Amendment Agreement to Framework Agreement agreeing to increase the maximum number of shares to be acquired through this proposed public tender offer to 120,059,970 shares, 77.94% stake, in accordance with Imexpharm Corporation’s foreign ownership cap requirements, and the Company will pay a maximum of VND 6,891,442,278,000. As of March 6, 2026 Livzon Pharmaceutical Group has officially received approval from the State Securities Commission of Vietnam. This allows them to proceed with a voluntary public tender offer for IMP shares. The transaction is subject to approval by merger control clearance, Permissible Foreign Ownership Limit, Absence of Material Adverse Change and other Customary Conditions. The number of shares intended to be sold by the Target Company’s shareholders does not reach the minimum threshold of 99,839,990 shares, representing 64.81% of the Target Company’s charter capital. The expected completion of the transaction is the date falling nine (9) months from the date of the Agreement. The transaction has been approved by the board of directors of Livzon Pharmaceutical Group Inc. Ernst & Young Vietnam Limited acted as due diligence provider to SK Investment Vina III Pte Ltd. Livzon Pharmaceutical Group Inc. (SZSE:000513) completed the acquisition of 67.88% stake in Imexpharm Corporation (HOSE:IMP) from SK Investment Vina III Pte Ltd., Cong Ty Co Phan Dau Tu Binh Minh Kim and KBA Investment joint stock company for VND 6 trillion on April 29, 2026. Shareholders of Livzon Pharmaceutical Group Inc. have reached the minimum threshold of 99,839,990 shares, representing 64.81% of Imexpharm Corporation.

Vietnamese (HOSE) Pharma Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

No independent directors

New major risk - Financial position

Dividend of ₫5,000 announced

Livzon Pharmaceutical Group Inc. (SZSE:000513) acquired 67.88% stake in Imexpharm Corporation (HOSE:IMP) from SK Investment Vina III Pte Ltd., Cong Ty Co Phan Dau Tu Binh Minh Kim and KBA Investment joint stock company for VND 6 trillion.

New major risk - Share price stability

First quarter 2026 earnings released

First quarter 2026 earnings released: EPS: ₫1,618 (vs ₫1,110 in 1Q 2025)

Upcoming dividend of ₫1,400 per share

Full year 2025 earnings released: EPS: ₫4,856 (vs ₫4,962 in FY 2024)

Full year 2025 earnings released: EPS: ₫1,538 (vs ₫1,474 in FY 2024)

Full year 2025 earnings released: EPS: ₫645 (vs ₫792 in FY 2024)

Vice General Director & Chairman recently sold ₫147m worth of stock

Traphaco Joint Stock Company, Annual General Meeting, Apr 17, 2026

Tipharco Pharmaceutical Joint Stock Company, Annual General Meeting, Mar 27, 2026